Toll Free: 1-888-928-9744

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 214 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016


Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016', provides an overview of the Waldenstrom Macroglobulinemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
- The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Waldenstrom Macroglobulinemia therapeutics and enlists all their major and minor projects
- The report assesses Waldenstrom Macroglobulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Waldenstrom Macroglobulinemia Overview 9 Therapeutics Development 10 Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10 Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11 Waldenstrom Macroglobulinemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Waldenstrom Macroglobulinemia - Products under Development by Companies 16 Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18 AbbVie Inc. 18 Amgen Inc. 19 arGEN-X BV 20 Aurigene Discovery Technologies Limited 21 Bayer AG 22 BeiGene, Ltd. 23 Calithera Biosciences, Inc. 24 Celgene Corporation 25 Genentech, Inc. 26 Gilead Sciences, Inc. 27 Hutchison MediPharma Limited 28 Idera Pharmaceuticals, Inc. 29 IGF Oncology, LLC. 30 Incyte Corporation 31 Juno Therapeutics Inc. 32 Karyopharm Therapeutics, Inc. 33 Merck KGaA 34 Millennium Pharmaceuticals, Inc. 35 Novartis AG 36 Takeda Pharmaceutical Company Limited 37 Vivolux AB 38 Waldenstrom Macroglobulinemia - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Combination Products 40 Assessment by Target 41 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 (INCB-039110 + INCB-040093) - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 765IGF-MTX - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 acalabrutinib - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 alisertib - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ARGX-110 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BGB-3111 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 bortezomib - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CA-4948 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 carfilzomib - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 CB-839 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 copanlisib hydrochloride - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 DI-B4 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 entospletinib - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 everolimus - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 HMPL-523 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 IMO-8400 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 INCB-40093 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 INCB-50465 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 itacitinib adipate - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 ixazomib citrate - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 JCAR-015 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 lenalidomide - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 ofatumumab - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 oprozomib - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 selinexor - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 121 Product Description 121 Mechanism of Action 121 R&D Progress 121 spebrutinib besylate - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 venetoclax - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 VLX-1570 - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 Waldenstrom Macroglobulinemia - Recent Pipeline Updates 130 Waldenstrom Macroglobulinemia - Dormant Projects 207 Waldenstrom Macroglobulinemia - Discontinued Products 208 Waldenstrom Macroglobulinemia - Product Development Milestones 209 Featured News & Press Releases 209 May 27, 2015: Amgen To present data from Oprozomib study at the 20th Congress of the EHA 209 Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting 209 Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 210 Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting 211 Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 211 Appendix 213 Methodology 213 Coverage 213 Secondary Research 213 Primary Research 213 Expert Panel Validation 213 Contact Us 213 Disclaimer 214
List of Tables
Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H1 2016 18 Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H1 2016 19 Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H1 2016 20 Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 21 Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H1 2016 22 Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H1 2016 23 Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H1 2016 24 Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H1 2016 25 Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H1 2016 26 Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H1 2016 27 Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H1 2016 28 Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 29 Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H1 2016 30 Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H1 2016 31 Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H1 2016 32 Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 33 Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H1 2016 34 Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 35 Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H1 2016 36 Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37 Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Assessment by Combination Products, H1 2016 40 Number of Products by Stage and Target, H1 2016 42 Number of Products by Stage and Mechanism of Action, H1 2016 45 Number of Products by Stage and Route of Administration, H1 2016 47 Number of Products by Stage and Molecule Type, H1 2016 49 Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H1 2016 130 Waldenstrom Macroglobulinemia - Dormant Projects, H1 2016 207 Waldenstrom Macroglobulinemia - Discontinued Products, H1 2016 208

List of Figures
Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 39 Number of Products by Top 10 Targets, H1 2016 41 Number of Products by Stage and Top 10 Targets, H1 2016 41 Number of Products by Top 10 Mechanism of Actions, H1 2016 44 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 44 Number of Products by Routes of Administration, H1 2016 46 Number of Products by Stage and Routes of Administration, H1 2016 46 Number of Products by Molecule Types, H1 2016 48 Number of Products by Stage and Molecule Types, H1 2016 48

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period


Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom


Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi


Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke


Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.